Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study . Ann Med Res [Internet]. 2021 May 25 [cited 2025 Apr. 9];27(1):0029-33. Available from: http://annalsmedres.org/index.php/aomr/article/view/591